U.S. Heart Pump Device Market Revenue & Forecast Analysis, 2026-2035

The U.S. heart pump device market was evaluated at USD 1,434.31 million in 2025 and is projected to grow at a CAGR of 11.6% from USD 1,585.64 million in 2026 to USD 4,252.53 million in 2035. The market expansion is primarily driven by the increasing prevalence of advanced heart failure, growing incidence of cardiogenic shock, and rising demand for mechanical circulatory support systems in critical cardiac care. Additionally, ongoing advancements in cardiac assist technologies, increasing utilisation of minimally invasive support devices, and the expanding adoption of heart pump devices across specialised cardiovascular centers are supporting the growth of the U.S. heart pump devices market.

Published: August 3, 2026
100 Pages

Market Overview

According to a 2023 study published in the Journal of the American College of Cardiology (JACC), left ventricular assist devices (LVADs) demonstrated improved long-term outcomes among patients with advanced heart failure, highlighting the growing clinical importance of mechanical circulatory support technologies in the United States.

The U.S. heart pump device market has grown steadily over the years, supported by continuous improvements in device durability, increasing availability of advanced circulatory support systems, and the expansion of specialised cardiac care programs across healthcare institutions. The introduction of next-generation heart pump technologies with enhanced monitoring and performance capabilities has further strengthened market adoption and clinical utilisation. For instance, in August 2024, Abbott announced a U.S. FDA-approved label update for its HeartMate 3™ LVAD based on findings from the ARIES-HM3 trial, reflecting continued advancements in heart pump device management and supporting market growth.

The U.S. heart pump device market is projected to experience significant growth throughout the forecast period due to increasing integration of digital monitoring capabilities, expanding research activities focused on long-term circulatory support solutions, and the growing adoption of patient-centric cardiac management approaches. The rising emphasis on improving post-procedural outcomes and quality of life among cardiac patients is also contributing to market expansion. For instance, by 2035, U.S. healthcare providers are expected to broaden the adoption of technologically advanced heart pump devices to support complex cardiovascular treatment pathways and improve patient outcomes.

U.S. Heart Pump Device Market Overview

Base Year Market Size (2025): USD 1,434.31 Million

CAGR: 11.6%

Forecast Year Market Size (2035): USD 4,252.53 Million

Major Players:

  • Abbott Laboratories

  • ABIOMED, Inc.

  • Medtronic plc

  • Getinge AB

  • SynCardia Systems, LLC

U.S. Heart Pump Device Market Trends

The U.S. heart pump device market is evolving rapidly due to advancements in device miniaturisation, increasing focus on remote patient management, and the growing adoption of data-driven cardiovascular care.

· The increasing development of compact heart pump devices is enabling improved patient mobility and treatment convenience.

· The growing incorporation of wireless monitoring and connectivity features is enhancing real-time patient tracking and clinical decision-making.

· The rising use of artificial intelligence and predictive analytics in cardiac care is supporting more personalised device management strategies.

· The increasing focus on reducing procedure-related complications is encouraging manufacturers to develop safer and more efficient heart pump systems.

Collectively, these trends are expected to support the continued growth of the U.S. heart pump device market by enhancing treatment effectiveness, improving patient management, and accelerating technological innovation.

U.S. Heart Pump Device Market Analysis

By Device Type

Ventricular Assist Devices (VADs) dominate the U.S. heart pump device market owing to widespread adoption.

Based on device type, the U.S. heart pump device market is categorised into ventricular assist devices (VADs), total artificial heart (TAH), and temporary mechanical circulatory support devices. The ventricular assist devices (VADs) segment leads the market with the highest market share in 2025.

By Procedure Type

High-Risk Percutaneous Coronary Intervention (PCI) dominates the U.S. heart pump device market due to increasing procedural volume

Based on procedure type, the U.S. heart pump device market is categorised into bridge to transplant (BTT), destination therapy, bridge to recovery, high-risk percutaneous coronary intervention (PCI), cardiogenic shock management, ventricular tachycardia (VT) ablation, and high-risk valvuloplasty. The high-risk percutaneous coronary intervention (PCI) segment leads the market with the highest market share in 2025.

By End-use

Hospitals dominate the U.S. heart pump device market owing to high patient volumes

Based on end-use, the U.S. heart pump device market is categorised into hospitals, cardiology centers, and others. The hospitals segment leads the market with the highest market share in 2025.

Key Companies Profiled

The U.S. heart pump device market features a competitive landscape with leading cardiovascular device manufacturers competing through advanced mechanical circulatory support technologies, innovative heart pump systems, and comprehensive cardiac care portfolios. Key players such as Abbott Laboratories, ABIOMED, Medtronic, Getinge AB, and SynCardia Systems hold a significant share of the market, supported by strong clinical expertise, extensive healthcare networks, and continuous technological advancements.

The market is highly competitive, with companies focusing on next-generation ventricular assist devices, minimally invasive circulatory support solutions, enhanced device performance, and advanced patient monitoring capabilities to strengthen their market positions. The increasing adoption of mechanical circulatory support therapies, evolving clinical requirements, and continuous innovation in cardiovascular technologies are further intensifying competition across the market.

U.S. Heart Pump Device Market Companies:

Some of the key companies operating in the U.S. Heart Pump Device Market include:

  • Abbott Laboratories

  • ABIOMED, Inc. (Johnson & Johnson MedTech)

  • Berlin Heart GmbH

  • BiVACOR Inc.

  • CardiacAssist, Inc.

  • Fresenius Medical Care AG & Co. KGaA

  • Getinge AB

  • Jarvik Heart, Inc.

  • Leviticus Cardio

  • LivaNova PLC

  • Medtronic plc

  • SynCardia Systems, LLC

  • Teleflex Incorporated

  • Terumo Corporation

  • World Heart Corporation

Market Segmentation

This study provides revenue growth and emerging trends across the U.S. levels from 2021 to 2035, segmenting the U.S. heart pump device market by-

Device Type (Revenue in USD Million, 2021 - 2035)

  • Ventricular Assist Devices (VADs)

    • Left Ventricular Assist Devices (LVADs)

    • Right Ventricular Assist Devices (RVADs)

    • BiVAD Ventricular Assist Devices (BiVADs)

  • Total Artificial Heart (TAH)

  • Temporary Mechanical Circulatory Support Devices

    • Percutaneous Ventricular Assist Devices (PVADs)

    • Intra-Aortic Balloon Pumps (IABPs)

    • Extracorporeal Membrane Oxygenation (ECMO)

Procedure Type (Revenue in USD Million, 2021 - 2035)

  • Bridge to Transplant (BTT)

  • Destination Therapy

  • Bridge to Recovery

  • High-Risk Percutaneous Coronary Intervention (PCI)

  • Cardiogenic Shock Management

  • Ventricular Tachycardia (VT) Ablation

  • High-risk Valvuloplasty

End-use (Revenue in USD Million, 2021 – 2035)

  • Hospitals

  • Cardiology Centers

  • Others

Table of Content

1. Methodology and Scope

1.1. Scope of the Study

1.1.1. Market Segmentation

1.1.2. Market Definition

1.1.3. Inclusions and Exclusions of the Study

1.2. Research Design

1.2.1. Base Year, Historical Data, and Forecast Period

1.2.2. Data Collection Methods

1.2.2.1. Secondary Sources

1.2.2.2. Primary Sources

1.2.3. Research Methodology

1.2.3.1. Base Year Calculation/ Parent Market Analysis, Company/ Brand Share Analysis, 2025 (Top-down Approach)

1.2.3.2. Volume-Price Approach (Bottom-up Approach)

1.2.3.3. Data Triangulation

1.2.4. Forecasting Model

1.3. Research Assumptions

1.4. Validation and Data Quality Control

1.5. List of Primary Sources

1.6. List of Secondary Sources

2. Executive Summary

2.1. Market Overview

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

3. Industry Outlook

3.1. Industry Ecosystem Analysis

3.2. Parent/ Ancillary Market Analysis

3.3. Market Dynamics

3.3.1. Drivers

3.3.2. Restraints/ Challenges

3.3.3. Opportunities

3.4. Value Chain Analysis

3.5. Technology Roadmap

3.6. Porters Analysis

3.7. PESTLE Analysis

4. Market Estimates and Forecasts, By Device Type, 2021 - 2035 (Market Size in USD Mn)

4.1. Ventricular Assist Devices (VADs)

4.1.1. Left Ventricular Assist Devices (LVADs)

4.1.2. Right Ventricular Assist Devices (RVADs)

4.1.3. BiVAD Ventricular Assist Devices (BiVADs)

4.2. Total Artificial Heart (TAH)

4.3. Temporary Mechanical Circulatory Support Devices

4.3.1. Percutaneous Ventricular Assist Devices (PVADs)

4.3.2. Intra-Aortic Balloon Pumps (IABPs)

4.3.3. Extracorporeal Membrane Oxygenation (ECMO)

5. Market Estimates and Forecasts, By Procedure Type, 2021 – 2035 (USD Mn)

5.1. Bridge to Transplant (BTT)

5.2. Destination Therapy

5.3. Bridge to Recovery

5.4. High-Risk Percutaneous Coronary Intervention (PCI)

5.5. Cardiogenic Shock Management

5.6. Ventricular Tachycardia (VT) Ablation

5.7. High-risk Valvuloplasty

6. Market Estimates and Forecasts, By End-use, 2021 – 2035 (USD Mn)

6.1. Hospitals

6.2. Cardiology Centers

6.3. Others

7. Market Estimates and Forecasts, By U.S., 2021 - 2035 (USD Mn)

7.1.1. U.S.

7.1.1.1. U.S. Heart Pump Device Market Estimates and Forecasts to 2035 (USD Mn)

7.1.1.2. Market Dynamics

7.1.1.3. Competitive Landscape

7.1.1.4. Regulatory Framework

7.1.1.5. Reimbursement Scenario

8. Competitive Landscape

8.1. Company Market Share Analysis, 2025

8.2. Company Tier Structure

8.3. List of Major Suppliers, By Key Countries

8.4. Key Company Positioning Analysis

8.5. Company Profile

8.5.1. Abbott Laboratories

8.5.2. ABIOMED, Inc. (Johnson & Johnson MedTech)

8.5.3. Berlin Heart GmbH

8.5.4. BiVACOR Inc.

8.5.5. CardiacAssist, Inc.

8.5.6. Fresenius Medical Care AG & Co. KGaA

8.5.7. Getinge AB

8.5.8. Jarvik Heart, Inc.

8.5.9. Leviticus Cardio

8.5.10. LivaNova PLC

8.5.11. Medtronic plc

8.5.12. SynCardia Systems, LLC

8.5.13. Teleflex Incorporated

8.5.14. Terumo Corporation

8.5.15. World Heart Corporation

9. Analyst Perspective

10. Related Reports

Revolution Insights Briefs

Stay informed with updates on related market reports and key industry topics.